On 12 December 2025, the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore’s Health Sciences Authority (HSA) announced a regulatory innovation corridor designed to accelerate access to breakthrough health technologies. The partnership allows developers to engage both regulators simultaneously and seek early, coordinated advice, reducing duplication while preserving regulatory oversight. Its significance extends beyond the UK and Singapore. As artificial intelligence becomes increasingly important in healthcare, from diagnosis and clinical decision support to hospital management and medical devices, health systems face a dual challenge: they must encourage innovation while ensuring that new technologies remain safe, trustworthy, and clinically useful. The UK–Singapore corridor suggests that purposeful regulatory collaboration between trusted partners can help meet this challenge. For the European Union, which faces mounting healthcare pressures but has also positioned itself as a global leader in trustworthy AI regulation, the question is whether similar cooperation could become part of the policy response. Against this backdrop, an EU–Singapore AI health innovation corridor offers a practical way for the EU to translate its regulatory ambition into responsible deployment, while supporting innovation in healthcare.
Author: Colette Gautier, Junior Researcher
Photo credits: Pexels